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Upon walking into a medical facility, such as a doctor’s office, 
the likelihood that an individual will leave with a prescription in 
hand is high.1 In 2016 alone, there were approximately 4.45 billion 
prescriptions issued throughout the United States (“U.S.”). This was 
a significant increase from 3.99 billion prescriptions dispensed six 
years earlier.2 The Center for Disease Control and Prevention re-
ported that between 2011 and 2014, 48.9 percent of individuals used 
at least one prescription medication in any given 30 day period.3 
Trending data seems to indicate that these numbers are growing.4 In 
the U.S. and Canada, this excessive prescribing of medication can 
be attributed to several factors, including preventative healthcare, 
pharmaceutical marketing, and, of course, the actual treatment of a 
medical disease or condition.5 With a heavy reliance on the utiliza-
tion of medications, local pharmacies primarily supply federally ap-
proved medications to customers. While federally approved drugs 
                                                                                                             
 1 Troyen Brennan, Why Are Physicians Still Prescribing High Cost Brand 
Name Drugs? Ask Pharma, REAL CLEAR HEALTH (May 14, 2017), 
https://www.realclearhealth.com/articles/2017/05/14/why_are_physi-
cians_still_prescribing 
_high_cost_brand_name_drugs_ask_pharma_110590.html; Geoffrey F. Joyce, 
Physician Prescribing Behavior and Its Impact on Patient-Level Outcomes, 
PUBMED (Sept. 24, 2013), http://pubmedcentralcanada.ca/pmcc/articles/ 
PMC3782257/. 
 2 Total Number of Medical Prescriptions Dispensed in the U.S. from 2009 
to 2016, STATISTA, https://www.statista.com/statistics/238702/us-total-medical-
prescriptions-issued/ (last updated 2019). 
 3 Therapeutic Drug Use, CDC, https://www.cdc.gov/nchs/fastats/drug-use-
therapeutic.htm (last updated May 3, 2017). 
 4 Id. 
 5 See Brennan, supra note 1; see also Joyce, supra note 1. 
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meet the demands of the population,6 some consumers face chal-
lenges in obtaining medications appropriate for specific allergies, 
dosages, and other needs.7 This is where the practice of pharmaceu-
tical compounding comes into play. 
Traditional pharmaceutical compounding involves the combin-
ing of individual pharmacological ingredients with the intent to cre-
ate a custom medication required by a patient.8 Traditional com-
pounding pharmacies may also modify commercially available 
drugs to fit an individual’s needs.9 On the other hand, outsourcing 
facilities, while also compounding drugs, differ in the respect that 
they do so on a much larger scale.10 These facilities are not neces-
sarily confined to creating personalized compounds for individu-
als.11 Rather, they may provide compounds to hospitals, long-term 
care facilities, and other providers during drug shortages.12 
Despite providing citizens with a necessary additional avenue to 
acquire medication, safety concerns regarding the general practice 
of pharmaceutical compounding have recently been in the spot-
light.13 In the U.S., the Food and Drug Administration (“FDA”) de-
termined that state government agencies have not done an adequate 
job of inspecting compounding facilities and enforcing required 
                                                                                                             
 6 See generally Amanda Baltazar, What is Drug Compounding?, VERY 
WELL (Feb. 4, 2017), https://www.verywell.com/what-is-drug-compounding-
2663861; see also Thomas Wong and Gordon Joseph, Canada’s Provincial Drug 
Formulation System, REGULATORY AFFAIRS PROFESSIONALS SOCIETY (Nov. 
2011). 
 7 Id. 
 8 Robert J. Timko & Philip E. M. Crooker, Pharmaceutical Compounding 
or Pharmaceutical Manufacturing: A Regulatory Perspective, 18 INT’L J. OF 
PHARMACEUTICAL COMPOUNDING 101, 102 (2014). 
 9 Id. 
 10 See generally Michael Werner, Drug Quality and Security Act Gives FDA 
Authority to Regulate Drug Compounding and Creates Uniform Federal Stand-
ards for Distribution, JDSUPRA (Nov. 19, 2013), https://www.jdsupra.com/legal-
news/drug-quality-and-security-act-gives-fda-47575/. 
 11 Id. 
 12 Id. 
 13 Tim Alamenciak, FDA Uncovers Widespread Problems at Compounding 
Pharmacies, THE STAR (Apr. 12, 2013), https://www.thestar.com/news/can-
ada/2013/04/12/fda_uncovers_widespread_problems_at_compounding_ 
pharmacies.html. 
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safety precautions.14 As noted by Jane Axelrad, associate director 
for policy and head of FDA’s compounding oversight activities, 
“[i]t’s really appalling what we’re seeing out there.”15 Axelrad re-
ported that FDA officials have seen unsanitary conditions and other 
problems at traditional compounding operations which are primarily 
regulated by the states.16 Inspectors have reported such violations as 
dead insects, dog beds, dog feces, and hair within close proximity of 
sterile compounding areas that could easily result in the contamina-
tion of the drugs being produced.17 Additionally, workers have been 
observed preparing sterile drug products without first covering their 
skin, which can lead to bacterial and particulate contamination.18 
Household coffee filters used to filter particulates, toaster ovens 
used for sterilization, and kitchen dishwashers and detergent used to 
clean sterile compounding equipment represents just a sample of the 
darker side of the compounding industry.19 Similarly, Health Can-
ada, the federal institution empowered to oversee drug safety and 
regulation, has discovered that compounding companies are slipping 
through regulatory cracks maintained by provincial/territorial regu-
latory bodies.20 While both the U.S. and Canada have initiated ac-
tions to ensure consumer-safe pharmaceutical compounds, each 
country has taken divergent approaches to accomplish this task. 
This article shall serve to explore the regulations created by the 
U.S.’ FDA and Canada’s National Association of Pharmacy Regu-
latory Authorities (“NAPRA”) and the manner in which they affect 
the operation of compounding facilities. More specifically, it will 
evaluate how these regulations can have a negative impact on both 
consumer drug prices and their availability. Part II of this article will 
                                                                                                             
 14 Ed Silverman, Safety Issues at Compounding Pharmacy Underscore Over-
sight Issues, STAT (Apr. 8, 2016), https://www.statnews.com/pharma-
lot/2016/04/08/compounding-pharmacy-drug-safety-fda/. 
 15 Kate Traynor, Compounding Oversight a Work in Progress for States, 




 16 Id. 
 17 Id. 
 18 Id. 
 19 Id. 
 20 Alamenciak, supra note 13. 
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provide a historical background regarding the delegation of regula-
tory jurisdiction over pharmaceutical compounding in both coun-
tries. Part III will summarize the recent federal actions taken by the 
U.S. and Canada to resolve compounding safety concerns. Part IV 
will compare the FDA’s aim for a centralized regulatory scheme 
versus Health Canada’s attempt at maintaining a decentralized reg-
ulatory regime. Part V will consider the current and future implica-
tions for drug prices and availability that may result from recent fed-
eral actions. 
II. BACKGROUND 
A. Pharmaceutical Compounding Regulations in the U.S. 
Prior to 2013 
In 1938, Congress enacted the Food, Drug, and Cosmetic Act 
(“FDCA”), giving the FDA regulatory jurisdiction over the produc-
tion of new medications.21 However, since compounding fell under 
the umbrella of pharmacy practice, the FDA considered the practice 
outside its regulatory regime.22 As such, individual states main-
tained regulatory power over licensing standards and professional 
practices for compounding.23 
For over fifty years, the FDA deferred to state regulations for 
pharmaceutical compounding without any interference.24 In 1992, 
an FDA agent reinterpreted the FDA’s regulatory authority under 
the FDCA, changing the classification of pharmaceutical com-
pounds to unapproved “new drugs.”25 This reinterpretation caused 
widespread panic within pharmaceutical communities.26 The conse-
quences for reclassifying compounds as “new drugs” would have 
made the pharmaceutical compounding practice both economically 
                                                                                                             
 21 Rebecca J. Riley, The Regulation of Pharmaceutical Compounding and the 
Determination of Need: Balancing Access and Autonomy with Patient Safety, 
HARVARD LAW SCHOOL (Apr. 2014), https://dash.harvard.edu/ 
bitstream/handle/1/8852177/Riley.html?sequence=1. 
 22 Id. 
 23 Id. 
 24 Id. 
 25 Id. 
 26 Riley, supra note 21. 
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and practicably infeasible.27 If all pharmacy-compounded drugs are 
“new drugs,” and therefore considered unlawful, they must first go 
through the approval process as specified by the FDA.28 Ultimately, 
the U.S. Court of Appeals for the Fifth Circuit affirmed their initial 
position from 1938 that pharmacy-compounded drugs were not con-
sidered “new drugs”29 requiring prior FDA approval, thereby leav-
ing regulations over pharmaceutical compounds to state govern-
ments.30 The implication of this new classification, although over-
turned, set the stage for a future power struggle between state and 
federal government control over pharmaceutical compounding reg-
ulations. 
Without delineated state regulations for pharmaceutical compa-
nies, the difference between compounding and manufacturing 
seemed indistinguishable to the FDA.31 This lack of transparency 
presented opportunities for pharmaceutical manufacturers to side-
step costly FDA regulations.32 The FDA, in response, issued a Com-
pliance Policy Guide for the “Manufacture, Distribution, and Pro-
motion of Adulterated, Misbranded, or Unapproved New Drugs for 
Human Use by State-Licensed Pharmacies” to provide some clarifi-
cation as to what falls under FDA regulations.33 Although the guide 
failed to clearly define what constituted manufacturing, the FDA 
newly asserted that it had full discretion over prosecuting what it 
believed to be illegitimate compounding practices.34 
In 1997, Congress passed the FDA Modernization Act 
(“FDAMA”), which provided some broad protections over the pro-
duction of drug compounds.35 These protections included explicit 
exemptions from the FDCA new drug, adulteration, and a misbrand-
                                                                                                             
 27 Id. 
 28 Med. Ctr. Pharmacy v. Mukasey, 536 F.3d 383, 389 (5th Cir. 2008). 
 29 Id. 
 30 Riley, supra note 21. 
 31 Id. 
 32 Id. 
 33 Id. 
 34 Id. 
 35 Id. 
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ing provision which was specifically aimed at preventing the label-
ing of drugs in a false or misleading manner.36 Additionally, the 
FDAMA provided a specified list of requirements that pharmacies 
had to meet in order for a drug to be considered “compounded.”37 
One of these requirements is that compounding must be limited to 
bulk substances that comply with the U.S. Pharmacopoeia (“USP”) 
or the National Formulary (“NF”).38 This was Congress’ first effort 
to provide public health protections to consumers of compounded 
drugs.39 The Act also required states to enter into a memorandum of 
understanding with the FDA to address the inordinate amount of in-
terstate distribution and provide state investigations for com-
plaints.40 This memorandum of understanding (“MOU”) represents 
a formal agreement between the FDA and federal, state, or local 
government agencies; academic institutions; and other entities.41 
The MOU constitutes an understanding between the parties but is a 
non-binding agreement.42 The intent of the MOU is to improve con-
sumer protection through the utilization of collective resources.43 
Should a state fail to enter into the memorandum, pharmacies resid-
ing in that state would be limited to interstate distribution of only 
five percent of prescriptions dispensed by a pharmacy.44 By creating 
this requirement, Congress maintained FDA regulatory jurisdiction 
over pharmaceutical compounding. 
The FDA’s authority over compounding once again expanded in 
2001, after the U.S. Supreme Court decided Thompson v. Western 
States Medical Center. The Supreme Court held that restrictions on 
advertising, stated in a provision in FDAMA, violated the First 
                                                                                                             
 36 Id.; Labeling Requirements – Misbranding, FDA, https://www.fda.gov/ 
MedicalDevices/DeviceRegulationandGuidance/Overview/DeviceLabel-
ing/GeneralDeviceLabelingRequirements/ucm052190.htm (last updated Oct. 27, 
2017). 
 37 Riley, supra note 21. 
 38 Id. 
 39 Id. 
 40 Id. 
 41 FDA Memoranda of Understanding, FDA, https://www.fda.gov/ 
AboutFDA/PartnershipsCollaborations/MemorandaofUnderstandingMOUs/de-
fault.htm (last updated July 17, 2016). 
 42 Id. 
 43 Id. 
 44 Riley, supra note 21. 
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Amendment.45 These restrictions included that the prescription be 
unsolicited and that the providers not advertise or promote the com-
pounding of any particular drug, class of drug, or type of drug.46 
Although the compounding industry gained advertising powers, the 
Supreme Court also reinstated the FDCA’s new drug, adulteration, 
and misbranding provisions, affirming consumer protection through 
accurate and truthful labeling and marketing.47 The Court reasoned 
that the reinstatement assisted in “[p]reserving the effectiveness and 
integrity of the FDCA’s new drug approval process.”48 
Since the Western States Medical Center decision, an outbreak 
of meningitis stemming from an improperly compounded sterile 
drug prompted the FDA to once again expand its jurisdiction.49 As 
a direct response to this incident, the FDA enacted the Drug Quality 
and Security Act in 2013.50 As part of this Act, specific steps were 
outlined to design and implement an electronic, interoperable sys-
tem to identify and trace certain prescription drugs as they are dis-
tributed in the U.S.51 Moreover, the Act was designed to enhance 
the FDA’s ability to help protect consumers from exposure to drugs 
that may be counterfeit, stolen, contaminated, or otherwise harm-
ful.52 
                                                                                                             
 45 See Thompson v. W. States Med. Ctr., 122 S. Ct. 1497, 1508‒09 (2002). 
 46 Id. at 1502‒03. 
 47 See id. at 1508‒09. 
 48 Id. at 1505. 
 49 Rachel M. Smith et al., Estimated Deaths and Illnesses Averted During 
Fungal Meningitis Outbreak Associated with Contaminated Steroid Injections, 
United States, 2012–2013, 21 EMERGING INFECTIOUS DISEASES 933, 934 (June 6, 
2015), https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4451895/. 
 50 Drug Quality and Security Act, Pub. L. No. 113-54 (2013), 
https://www.congress.gov/bill/113th-congress/house-bill/3204. 
 51 Drug Supply Chain Act, FDA, https://www.fda.gov/Drugs/Drug-
Safety/DrugIntegrityandSupplyChainSecurity/DrugSupplyChainSecurityAct/ 
(last updated Nov. 28, 2017); see also Margaret A. Hamburg, New Law Enhances 
Safety of Compounded Drugs and Protection of the Drug Supply Chain, FDA 
VOICE (Dec. 2, 2013), https://blogs.fda.gov/fdavoice/index.php/2013/12/new-
law-enhances-safety-of-compounded-drugs-and-protection-of-the-drug-supply-
chain/. 
 52 Id. 
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B. Pharmaceutical Compounding Regulations in Canada 
Prior to 2016 
In 1920, Canada’s FDA equivalent, the Federal Department of 
Health enacted the Food and Drugs Act to regulate the production, 
sale, and importation of food, drugs, cosmetic, and medical de-
vices.53 Additionally, by the late 1920s, the Food and Drugs Regu-
lations were created to set the standards for the “composition, 
strength, potency, quality, or other property of [an] article of food or 
drug.”54 However, much like in the U.S., the Food and Drug Act and 
Regulations provided federal regulatory power over drug manufac-
turers but not compounding pharmacies.55 This distinction was not 
clarified until 2000, when Health Canada published a policy titled 
“Manufacturing and Compounding Drug Products in Canada.”56 
The aim of this policy was to better regulate the process federal reg-
ulators, provincial/territorial regulators, and healthcare profession-
als must follow when dealing with jurisdictional issues related to 
compounding and manufacturing.57 The guiding principle of this 
policy maintained that compounding must be a legitimate part of the 
practice of regulated healthcare professionals and must not be used 
to bypass the federal drug review and approval system.58 The adop-
tion of this policy would enable a consistent Canada-wide approach 
to ensure that all products and activities are appropriately regu-
lated.59 
                                                                                                             
 53 Frequently Asked Questions – Food and Drug Regulations, GOV’T OF 
CANADA (June 27, 2016), https://www.canada.ca/en/health-canada/corpo-
rate/about-health-canada/legislation-guidelines/acts-regulations/frequently-
asked-questions-food-drug-regulations.html; see also Food and Drugs Act, R.S.C. 
1985, c. F-27 (Can.). 
 54 Id. 
 55 Health Products and Food Branch Inspectorate, Policy on Manufacturing 




 56 Id. 
 57 Id. 
 58 Id. 
 59 Id. 
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In 2009, the Health Products and Food Branch Inspectorate pro-
vided additional clarification, publishing an administrative docu-
ment noting the distinction between manufacturing and compound-
ing.60 Regulatory jurisdiction for pharmaceutical compounding was 
delegated to provinces/territories.61 Health Canada reasoned that 
compounding is a licensed act that falls within the scope of phar-
macy practice.62 As such, any professional engaged in the com-
pounding process must comply with individual province/territory li-
censing regulations.63 With compliance being met, the risk involved 
in compounding falls entirely on health professionals.64 
To the contrary, pharmaceutical companies that are deemed 
“manufacturers” must comply with more restrictive federal regula-
tions.65 In order for a company to sell a manufactured drug, Health 
Canada must review the product’s quality, safety, and efficacy.66 
Moreover, manufactured drugs require a Drug Identification Num-
ber and/or Notice of Compliance in order to be sold.67 These addi-
tional regulations reduce the production of dangerous or otherwise 
unsatisfactory drugs.68 
Should there be any uncertainty as to whether drug production 
can be clearly categorized as manufacturing or compounding, a dis-
cussion between the federal government and provincial/territorial 
bodies takes place to make a final determination.69 Yet, because 
each decision is decided on a case-by-case basis,70 some manufac-
turing activity may be incorrectly categorized as compounding and 
thus, bypass certain safety standards. This has ultimately led to a 
number of large scale health issues.71 For example, in an incident 
                                                                                                             
 60 Id. 
 61 Id. 
 62 Id. 
 63 Id. 
 64 Id. 
 65 Id. 
 66 Id. 
 67 Id. 
 68 Id. 
 69 Id. 
 70 Id. 
 71 Amina Zafar, Chemotherapy Outsourcing Done by Hospitals Across Can-
ada, CBC NEWS (Apr. 25, 2013), http://www.cbc.ca/news/health/chemotherapy-
outsourcing-done-by-hospitals-across-canada-1.1308762. 
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that left 1200 patients in New Brunswick and Ontario with lower-
than-expected dosages of the cancer drug Gemcitabine, hospitals in 
at least three Canadian provinces revealed that they outsourced their 
chemotherapy preparations through compounding facilities.72 As a 
result, Health Canada is attempting to establish uniform safety 
standards that provinces/territories will be required to individually 
adopt and implement.73 
III. SUMMARY OF THE CHANGES IN FEDERAL REGULATIONS FOR 
PHARMACEUTICAL COMPOUNDING IN THE U.S. AND CANADA 
To understand how the newly implemented regulatory schemes 
for pharmaceutical compounding between the U.S. and Canada di-
verge, it is important to first carefully analyze each scheme inde-
pendently. 
A. U.S. Drug Quality and Security Act 
When a New England pharmaceutical compounding company in 
Framingham, Massachusetts produced a tainted steroid medication 
that resulted in a deadly meningitis outbreak, the FDA made the de-
cision to intervene.74 The outbreak led to 64 deaths and 751 non-
lethal injuries.75 As a direct response to this incident, the FDA cre-
ated and enacted the Drug Quality and Security Act.76 The Drug 
Quality and Security Act amended the Food, Drugs, and Cosmetics 
Act (“FDCA”), granting the FDA additional authority to regulate 
                                                                                                             
 72 Id. 
 73 Model Standards of Pharmacy Compounding of Non-Hazardous Sterile 
Preparations, NAPRA (Nov. 1, 2016), https://napra.ca/sites/default/files/2017-
09/Mdl_Stnds_Pharmacy_Compounding_NonHazardous_Sterile_Prepara-
tions_Nov2016_Revised_b.pdf. 
 74 Rachel M. Smith et al., Estimated Deaths and Illnesses Averted During 
Fungal Meningitis Outbreak Associated with Contaminated Steroid Injections, 
United States, 2012–2013, 21 EMERGING INFECTIOUS DISEASES 933, 934 (June 6, 
2015), https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4451895/. 
 75 Multistate Outbreak of Fungal Meningitis and Other Infections – Case 
Count, CTR. FOR DISEASE CONTROL AND PREVENTION (Oct. 30, 2015), 
https://www.cdc.gov/hai/outbreaks/meningitis-map-large.html. 
 76 Drug Quality and Security Act, Pub. L. No. 113-54 (2013). 
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the manufacturing of sterile pharmaceutical compounds.77 Specifi-
cally, Section 503A of the FDCA was amended to regulate tradi-
tional compounders.78 The Drug Quality and Security Act also im-
plemented a new provision, Section 503B, to regulate larger out-
sourcing drug facilities.79 
Section 503B allows compounders to voluntarily register as an 
outsourcing facility, which provides exemptions from FDA ap-
proval and labeling requirements.80 In addition, registering as an 
outsourcing facility allows for the compounding of drugs without 
patient-specific prescriptions.81 While it would seem that most com-
panies would be disposed to register as an outsourcing facility, there 
are a considerable number of disadvantages. Outsourcing facilities 
are required to pay an FDA imposed annual registration fee of over 
$15,000.82 The compounder is then subjected to federal inspections 
on a “risk-based” schedule.83 Due to the FDA’s extremely strict reg-
ulations, registered outsourcing facilities may be required to pay re-
inspection fees of over $15,000 if noncompliance is identified.84 Ad-
ditionally, outsourcing facilities must also comply with the U.S. 
Food and Drug Administration’s Current Good Manufacturing Prac-
                                                                                                             
 77 Id. 
 78 Examining Implementation of the Compounding Quality Act, U.S. FOOD 
AND DRUG ADMIN. (Jan. 30, 2018), https://www.fda.gov/NewsEvents/Testi-
mony/ucm594297.htm. 
 79 Information for Outsourcing Facilities, U.S. FOOD AND DRUG ADMIN., 
https://www.fda.gov/Drugs/ 
GuidanceComplianceRegulatoryInformation/PharmacyCompound-
ing/ucm393571.htm. (last visited Mar. 18, 2019). 
 80 Id. 
 81 Information Concerning Outsourcing Facilities Registration, U.S. FOOD 
AND DRUG ADMIN., https://www.fda.gov/Drugs/GuidanceComplianceRegulato-
ryInformation/PharmacyCompounding/ucm389118.htm. (last visited Mar. 18, 
2019). 
 82 Human Drug Compounding Outsourcing Facility Fees, U.S. FOOD AND 
DRUG ADMIN., https://www.fda.gov/ForIndustry/UserFees/HumanOutsourcing-
FacilityUserFee/default.htm. (last visited Mar. 18, 2019). 
 83 Id. 
 84 Id. 
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tice (“CGMP”) regulations when producing pharmaceutical com-
pounds.85 The CGMP requirements utilize the same strict regula-
tions used by the FDA for approving drugs.86 Systems must be put 
into place to assure proper design, monitoring, and control of man-
ufacturing processes and facilities.87 However, adherence to the 
CGMP regulations, while assuring the identity, strength, quality, 
and purity of the drug,88 drives production costs up.89 This is further 
exacerbated by the expense of extensive monitoring, documenta-
tion, and reporting.90 
Should the compounding facility opt not to register as an out-
sourcing facility, it will be governed by 503A and state regula-
tions.91 While quality assurance standards are similar to those re-
quired in 503B, the individual prescription mandate in 503A pre-
vents traditional compounding pharmacies from compounding 
products in large quantities.92 Section 503A limits traditional com-
pounding pharmacies to stocking no more than a 30-day supply of 
any specific compounded drug.93 This can be problematic as phar-
macists must rely on past transactions with consumers as a measure 
                                                                                                             
 85 Information for Outsourcing Facilities, supra note 79. 
 86 Facts About the Current Good Manufacturing Practices (CGMPs), U.S. 
FOOD AND DRUG ADMIN., https://www.fda.gov/drugs/developmentapprovalpro-
cess/manufacturing/ucm169105.htm. (last visited Mar. 18, 2019). 
 87 Id. 
 88 Id. 
 89 See Stricter Drug Compounding Regulations Complicate Ophthalmology 




 90 Id.; see generally Center for Drug Evaluation and Research: Outsourcing 
Facility Information, FDA (Sept. 2017), https://www.fda.gov/down-
loads/Drugs/GuidanceComplianceRegulatoryInformation/PharmacyCompound-
ing/UCM577334.pdf. 
 91 Examining Implementation of the Compounding Quality Act, supra note 
78. 
 92 Prescription Requirement Under Section 503A of the Federal Food, Drug, 




 93 Id. 
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to predict the quantities of each drug necessary to meet future de-
mand. 
With a higher cost of production and smaller supply of products, 
traditional compounding pharmacies may be forced out of the mar-
ket. Furthermore, with the FDA encouraging state enforcement ini-
tiatives, traditional compounding pharmacies risk being fined for 
producing drugs in excess due to innocent or incorrect calculations 
for future demand. 
B. Canada’s Model Standards for Pharmacy Compounding 
Similar to the U.S., a health crisis resulted in the restructuring of 
drug compounding regulations in Canada. After the 2013 incident 
in which 1,200 people in Ontario and New Brunswick received 
lower-than-intended doses of chemotherapy,94 Ontario amended 
provincial regulations to prevent this type of incident from being 
repeated.95 Canada clearly needed higher and uniform standards for 
compounding drugs.96 As a result, the NAPRA instituted the Model 
Standards for Pharmacy Compounding.97 The Model Standards pro-
vide the minimum requirements to be applied in each province/terri-
tory.98 It is important to note that these Model Standards are com-
prised of three phases implemented over a four year period of time.99 
The initial 2016 release of these national standards for compounding 
preparations is scheduled to be fully phased in by 2021.100 Canadian 
pharmaceutical compounders will be encouraged to follow the four-
year phased in approach to ensure they meet all requirements by 
                                                                                                             
 94 Zafar, supra note 71. 
 95 See generally Jake J. Thiessen, A Review of the Oncology Under-Dosing 
Incident, ONTARIO MINISTRY OF HEALTH AND LONG-TERM CARE (July 12, 2013), 
http://www.health.gov.on.ca/en/public/programs/cancer/drugsupply/docs/ 
report_thiessen_oncology_under-dosing.pdf. 
 96 See id. 
 97 See id. 
 98 Bob Nakagawa, 125th Anniversary Conference and Gala: The Future of 
Pharmacy, C. OF PHARMACISTS OF BRIT. COLUMBIA (Sept. 17, 2016), http://li-
brary.bcpharmacists.org/5_Programs/5-3_PDAP/5197-
CPBC125_PowerPoint.pdf. 
 99 Implementing the New Model Standards For Pharmacy Compounding, C. 
OF PHARMACISTS OF BRIT. COLUMBIA, http://www.bcpharmacists.org/compound-
ing (last visited Mar. 25, 2019). 
 100 Id. 
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May 2021, when the new bylaws become fully effective.101 Should 
any compounding manufacturer repeatedly fail to meet these stand-
ards, a decision will have to be made regarding permanent termina-
tion of sterile compounding preparation.102 
The NAPRA has released the three subsections for Model Stand-
ards for Pharmacy Compounding.103 The three subsections consist 
of Model Standards for Non-Hazardous Sterile Preparation, Hazard-
ous Sterile Preparations, and Non-Sterile Preparations.104 With con-
sideration to commercial compounding, the NAPRA has imple-
mented stricter regulations regarding personnel handling and super-
vision of the production of compounded drugs; policies and proce-
dures; facility design and required equipment; and general mainte-
nance logs.105 As an example, the Model Standards specify more 
stringent requirements depending on the complexity and risk of the 
compounding activity, the use of hazardous products in the produc-
tion, and workflow.106 
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IV. CENTRALIZED VERSUS DECENTRALIZED REGULATORY 
FRAMEWORKS 
A. State Oversight of Compounding Pharmacies 
With the meningitis outbreak instilling panic within the general 
population in 2012, the U.S. federal government began investigating 
compounding pharmacies searching for safety violations.107 While 
the FDA has issued warnings and recommendations identifying spe-
cific safety violations, the identified compounders and states refuse 
to accept the FDA as having ultimate authority in regards to phar-
macy practice.108 Although the Drug Quality and Security Act al-
lows the FDA to inspect facilities and enforce regulations, the over-
lap between state and federal regulations, in addition to the disagree-
ments between regulators, has resulted in confusion and a lack of 
accountability.109 
State regulations, not being as rigorous as FDA regulations, have 
become the crux of ineffective government regulation.110 An analy-
sis by PEW Charitable Trusts, a public policy organization, deter-
mined that approximately only half of the states require compound-
ing pharmacies that produce sterile medications to fully comply with 
recognized quality standards.111 Furthermore, the PEW Charitable 
Trust states that there is great variability between the breadth of USP 
797 requirements, which are the recognized and accepted quality 
standards, and enforcement between states.112 “Regarding com-
pounding inspector qualifications, only 70% of the states required a 
pharmacist license, only 60% required prior experience within a 
pharmacy, and only 58% required training on applicable USP stand-
ards.”113 It is an alarming issue that twenty-eight out of forty-three 
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respondents to the PEW survey did not require specialized training 
in the compounding of sterile medication.114 
Discrepancies between the FDA and the Texas State Board of 
Pharmacy, in regulating compounding pharmaceutical manufactur-
ers, illuminates the potential conflicts and confusion between the 
two regulatory schemes.115 In 2016, the FDA “uncovered multiple 
egregious, life-threatening problems in a compounding pharmacy’s 
process for making sterile drugs.”116 However, the FDA remains 
powerless to force the compounder to abide by any safety recom-
mendations.117 In response to the FDA’s allegations along with Pub-
lic Citizen’s, a consumer advocacy group, plea to suspend the com-
pounder’s license, the Texas State Board of Pharmacy sent its own 
inspector to investigate the matter.118 The state inspector determined 
that the compounder, IV Specialty, was properly abiding by state 
regulations and that the public was not in any imminent danger.119 
As such, the Texas State Board of Pharmacy refused to halt the com-
pounder’s production, issue a recall of drugs manufactured and de-
livered, or suspend the compounder’s license as recommended by 
the FDA and Public Citizen.120 
Apart from the varying quality standards between states, sixty 
percent of states of the forty-three responding states to the PEW sur-
vey do not require compounding pharmacies to track and report ad-
verse events.121 Additionally, compounding activity in sixteen states 
is completely unsupervised by state regulators.122 Of the forty-three 
responding states, only fifty-three percent actually conduct annual 
routine inspections of compounding facilities creating sterile 
drugs.123 Should any safety issue be identified during the routine an-
nual inspection, a written response from the pharmacy describing 
how the issues were remediated would be required.124 However, 
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only two-thirds of the surveyed states conduct a follow-up inspec-
tion to ensure compliance.125 It is this lack of accountability that re-
sults in egregious violations and provides the potential for the dis-
tribution of hazardous drugs. 
The Pharmacy Compounding Accreditation Board (PCAB) as-
sesses pharmacies that compound medication, ensuring their com-
pliance with U.S. Pharmacopeial Convention guidelines, which re-
duces safety risks.126 However, compounding pharmacies are not re-
quired by states to be accredited by the PCAB, thereby removing a 
necessary level of protection for public health.127 
This variation in state oversight has raised questions regarding 
state regulators’ ability to protect public health and has prompted 
Congress to consider granting the FDA even more regulatory au-
thority over the compounding industry.128 
B. U.S. FDA’s Aim Towards Centralized Regulation for 
Compounding Drugs 
The lack of specificity within sections 503A and 503B of the 
Compounding Quality Act has left the door open for considerable 
misinterpretation.129 The main issue is that state laws and regula-
tions are not aligned with federal laws and regulations.130 States vary 
on how they define an outsourcing facility and therefore, may fail to 
properly recognize and report an outsourcing facility to the FDA.131 
New York, for example, has updated statutes and regulations to in-
clude a definition and category for outsourcing facilities.132 Other 
states, however, categorize outsourcing facilities with compounding 
pharmacies, manufacturers, or distributors, which allows these 
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states to maintain control over their outsourcing facilities.133 Be-
cause Congress, in the creation of section 503B, did not mandate 
that outsourcing facilities register with the FDA, the FDA lacks ef-
fective regulation.134 This lack of control allows for safety violations 
by compounding facilities, causing public health issues.135 
While the FDA attempts to entice compounders to register as an 
outsourcing facility by providing incentives, including bypassing 
the prescription requirement in 503A, state regulators negate these 
incentives.136 As a number of states have no specific guidelines to 
handle 503A federal violations, they ultimately permit traditional 
compounding pharmacies to compound without individual patient 
prescriptions.137 Currently, nine states have no intent to discipline 
pharmaceutical manufacturing violators or require these compound-
ing pharmacies to register as outsourcing facilities with the FDA.138 
Once again, accountability seems to be absent. As such, only 73 out 
of 1,500 compounding pharmacies have registered as of December 
8, 2017.139 
While the FDA has the authority to take legal action against ster-
ile compounding pharmacies that are allegedly conducting unsafe 
practices, it has rarely done so and remains cautious about overstep-
ping state authority.140 Furthermore, although the FDA has been ag-
gressively inspecting compounding pharmacies, it relies on commu-
nication with state regulators regarding serious adverse events and 
quality problems reports.141 As noted above, with sixty-three percent 
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of forty-three states not requiring compounders to track and report 
adverse events, the FDA has little knowledge and is therefore, lim-
ited in its ability to protect public health.142 
With ineffective state oversight over compounding pharmacies 
and enforcement of the Drug Quality and Security Act, the FDA has 
requested greater jurisdiction over sterile compounded drugs.143 
Moreover, the Biotechnology Innovations Organization (“BIO”), 
The Pharmaceutical Research and Manufacturers of America 
(“PhRMA”), PEW Charitable Trusts and other groups sent letters 
urging Congress to provide the FDA with additional oversight au-
thority over drug compounders.144 These organizations stress that 
“[i]f [the] FDA is not permitted to maintain that line between tradi-
tional compounding and outsourcing facilities, patients are put at 
risk, states and compounding pharmacies will not have clear regula-
tory guidance, and the lessons of the national meningitis outbreak 
will have been forgotten.”145 
Fairleigh Dickinson University School of Pharmacy and Health 
Sciences has published a list of ten recommendations to improve the 
quality and ensure the safety of compounded drugs. The top three 
recommendations provide the FDA with additional authority over 
facilities producing sterile compounds. The three are as follows: 
1. Congressional legislation removing ambiguity from provi-
sions of section 503A and empowering the FDA to enforce 503A.146 
2. Congressional legislation that requires outsourcing facilities 
to register with the FDA, thereby, mandating operations under 
CGMP requirements. Such action will allow inspection of such fa-
cilities to be governed by the FDA (rather than pharmacy licensing 
boards), which has the potential to drive closure of the sterile com-
pounding facilities not in compliance.147 
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3. Congressional legislation that mandates adverse event re-
porting and complete product labeling by all compounding pharma-
cies, not just registered outsourcing facilities.148 
Although these are nothing more than recommendations, the 
combination of this publication and the letters sent to Congress by 
the BIO, PhRMA, PEW, and the other organizations illustrates the 
overall agreement that a more centralized regulatory framework 
needs to be implemented. However, with the overarching concern 
regarding the separation of powers, the time it may take to enact 
these recommendations may be well after the occurrence of another 
health crisis caused by unsafe compounded medications. Until Con-
gress provides additional clarity for state and federal regulators, con-
sumers of compounded drugs remain extremely vulnerable. 
C. Proposed Legislation and State Pushback 
As recently as June 2017, a new bill sponsored by Congressmen 
H. Morgan Griffith (R-VA) and Henry Cuellar (D-TX) was pro-
posed that would certainly weaken consumer protection.149 This bill 
would permit “traditional compounding pharmacies to distribute 
compounded drugs within a state without requiring an individual 
prescription (only a ‘drug order’) and without being required to fol-
low CGMP standards as [is required by] outsourcing facili-
ties . . . .”150 If passed, the bill would attenuate the 2013 law that 
created outsourcing procedures and guidelines.151 Compounding 
companies would be able to continue producing pharmaceuticals 
without having to register, without having to report adverse events, 
and without having to pay the user fees that are required with regis-
tering as an outsourcing facility.152 More importantly, compounding 
pharmacies would not be required to follow CGMP standards, 
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thereby saving costly expenses.153 The potential of this bill could be 
catastrophic, taking the industry back to pre-2013 standards and rec-
reating conditions that could result in outbreaks similar to that which 
occurred with the New England Compounding Center.154 It is no 
surprise that HR2871 is strongly supported by the International 
Academy of Compounding Pharmacists, a trade group that donated 
to both Griffith’s and Cuellar’s political campaign.155 With all the 
latitude and lower costs this bill would afford compounding compa-
nies, it would behoove these companies to support such legislation, 
irrespective of the potential consequences. 
D. Health Canada so Far Maintains a Decentralized 
Regulatory Scheme 
Unlike U.S. states, which take pride in considering themselves 
the “laboratories of democracy,”156 Canada has been working on re-
solving its national unity crisis by attempting to establish provincial 
equality.157 Provincial equality pertains to jurisdictional control, po-
litical representation, and economic equality.158 Simply put, Cana-
dian provinces are focused on making sure policies extended by the 
federal government and their outcomes are proportionally equal 
within each province. As long as a federal policy promotes uni-
formity, provinces are more open to accepting and enforcing that 
policy, especially when it is not politicized. 
A recent ISMP Canada Safety Bulletin makes clear the present 
state of the compounding industry.159 Canadian patients diagnosed 
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with cancer have the option of choosing alternative medical ap-
proaches, including naturopathy, for treatment of their conditions.160 
In one incident, reported as recently as January 2018, a cancer pa-
tient was prescribed a tissue and wound healing formulation for 
postsurgical healing support.161 The formulation was administered 
intravenously and contained selenium prepared by a compounding 
pharmacy.162 Upon hospital discharge, after surgical excision of a 
cancerous tumor and subsequent to the administration of the sele-
nium formulation, the patient began to experience hypotension, 
shortness of breath, and chest pain and ultimately passed away.163 
Postmortem investigations revealed that the selenium concentration 
in the infused formula was one thousand times greater than intended, 
which likely contributed to the patient’s death.164 
In another incident, after 1,200 people received lower-than-in-
tended doses of chemotherapy in New Brunswick and Ontario,165 
Canada’s federal and provincial/territorial governments became 
concerned with the manner in which to protect the public health 
from unsafe compounded drugs.166 The Ontario Ministry of Health 
and Long-Term Care commissioned Dr. Jake Thiessen, a pharma-
cokinetic specialist, as an independent investigator to determine the 
cause of the incident and provide recommendations.167 In Dr. Thies-
sen’s report, he pointed out that the vendor who produced the doses 
of chemotherapy provided inter-provincial services because both 
New Brunswick and Ontario hospitals were affected.168 As such, 
provinces and territories throughout Canada were at risk of experi-
encing similar incidents unless changes were made on a national 
scale.169 One of Dr. Thiessen’s recommendations provided that the 
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NAPRA work closely with Health Canada as a means of creating 
the best objective standards for sterile and non-sterile product prep-
aration within a licensing pharmacy.170 
Dr. Thiessen’s recommendation to look to the NAPRA essen-
tially made the public health issue revolving around pharmaceutical 
compounding less politicized. The NAPRA is comprised of mem-
bers from each province and territory that are represented on the as-
sociation’s board of directors.171 With each provincial and territorial 
regulatory body collaborating, the NAPRA has successfully pub-
lished three subsections of the Model Standards for Pharmacy Com-
pounding to be adopted on a national basis.172 As such, provinces 
and territories continue to retain full control over compounding ac-
tivity, thereby resolving international unity issues and maintaining a 
consistent approach. 
E. The NAPRA Model Standards Increase Accountability 
Within the Pharmacies 
The NAPRA Model Standards for Pharmacy Compounding is a 
comprehensive set of regulations designed to increase safety stand-
ards for the preparation of sterile and non-sterile compounded 
drugs.173 In contrast to the U.S., where Congress granted the FDA 
regulatory authority to oversee compounding pharmacies,174 the 
NAPRA Model Standards preserves the authority of ensuring the 
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safe preparations of compounded drugs solely within the provin-
cial/territorial regulatory authorities.175 Luckily, the NAPRA Model 
Standards vastly raises the criteria for hiring personnel, enforcing 
policies and procedures, ensuring clean facilities and proper equip-
ment, and keeping a general maintenance log.176 Adoption of the 
Model Standards should make provincial/territorial oversight easier 
and lower the risk of public health issues. 
With regards to personnel involved with sterile preparations, in-
cluding pharmacists, pharmacist technicians, and pharmacist assis-
tants, each individual must attain the appropriate education, experi-
ence, and required trainings and assessments in order to participate 
in the process of compounding of sterile preparations.177 The train-
ing and assessments include the following: 
[R]eading and understanding the policies and proce-
dures related to compounded sterile preparations; 
theoretical training, with assessment covering vari-
ous topics . . . ; individual practice training and as-
sessment in the workplace clean room . . . ; assess-
ment of aseptic techniques, based on gloved fingertip 
sampling (GFS) and media fill tests, for various types 
of sterile preparations to be compounded.178 
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Trainings and assessments must be complete at least once a year 
in the work place for personnel operating at low or medium risk lev-
els and at least twice a year for preparation with high risk levels.179 
Should any compounding personnel fail an assessment, the work 
shall be immediately halted and retraining will be required.180 All 
assessments and trainings are recorded in each employee’s file and 
must be retained for a period specific to the provincial/territorial au-
thority.181 
Pharmacies conducting sterile preparation require an on-site 
sterile compounding supervisor, separate from a pharmacy manager 
or department head.182 The sterile compounding supervisor ensures 
that requirements by the Model Standards are met and all records 
are available for audit and inspection by provincial/territorial au-
thorities.183 
One of the main responsibilities for a sterile compounding su-
pervisor is to establish the content for all policies and procedures.184 
Further, the content must provide a detailed description of all activ-
ities occurring in the pharmacy.185 Procedures must be clear and 
concise, follow a standard format, and include an index for easy ac-
cess.186 Established policies and procedures must be promptly up-
dated should there be a change in practice or standards.187 Even 
without changes, policies and procedures must be reviewed every 
three years by the sterile compounding supervisor.188 If the com-
pounding of a drug is prepared by more than one pharmacy, as per-
mitted by provincial/territorial legislation, the dispensing pharmacy 
should include information about the acquisition of compounded 
sterile preparations for patients in its policies and procedures.189 
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Compliance with the policies and procedures prescribed by the ster-
ile compounding supervisor ensures proper quality and safety of the 
prepared drugs. 
The Model Standards for Compounding of Non-Sterile Prepara-
tions similarly follow suit as a means of increasing accountability 
within compounding facilities. Along with the specified training and 
assessment of personnel, specialized equipment, and policies and 
procedures for quality assurance, Non-Sterile Preparations specifi-
cally require that a risk assessment be completed prior to compound-
ing to identify the appropriate level of requirements to minimize 
contamination of each compounded product and provide adequate 
protection for personnel.190 There are three levels of requirements, 
Level A, B, and C, where compounded drugs are categorized by how 
the product is defined under the USP General Chapter <795>, the 
quantity of ingredients being compounded, and whether the product 
is hazardous.191 Level A has the lowest requirement, requiring only 
a separate space designated for compounding. However, Level B 
and C have more stringent requirements. For example, one of the 
requirements under Level C is a well-ventilated room with appro-
priate air exchange and negative pressure.192 Even though account-
ability may seem lower for certain non-sterile compounded drugs, 
such as simple and moderate compounds categorized as Level A, 
public threat is lessened for non-sterile compounded drugs based on 
the modality of consumer administration (i.e. oral vs. injectable).193 
Regardless, by conducting a risk assessment in compliance with the 
NAPRA Model Standards, consumers of non-sterile compounded 
drugs are better protected from incurring health problems. 
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As a whole, the NAPRA Model Standards increase accountabil-
ity within compounding pharmacies by requiring general mainte-
nance logs.194 These records include either computerized or paper 
documentation regarding activities such as cleaning and disinfect-
ing, certification and maintenance of the facility, risk assessment, 
and certification of the primary engineering control and mainte-
nance of other equipment.195 Verification of proper operation of 
equipment and instruments (i.e. calibration, temperatures for differ-
ent types of storage) must be documented.196 All general mainte-
nance logs must be retained according to the respective provin-
cial/territorial authority, thus allowing provinces/territories to en-
sure that compounding facilities remain in compliance with these 
enhanced safety standards.197 
Through the implementation of these three subsections of the 
NAPRA Model Standards for Compounding, the combination of 
oversight by provincial/territorial authorities and accountability by 
the pharmacies should be effective in ensuring safe compounding. 
F. Canada’s Possible Future Regulatory Disaster 
While the NAPRA Model Standards for Pharmacy Compound-
ing provide the framework for safe preparation, Canada now seems 
to be revisiting Dr. Thiessen’s recommendations. Recently, Health 
Canada initiated a regulatory initiative to create a new framework 
for addressing commercial compounding.198 Current “Policy on 
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Manufacturing and Compounding Drug Products in Canada” de-
fines the difference between manufacturing and compounding in or-
der to determine whether an activity is provincially/territorially or 
federally regulated.199 However, without concise regulatory over-
sight, a gap remains, creating public health issues.200 
For Health Canada, there are inherent reasons to justify a cau-
tious approach to this new regulatory initiative. Prior to creating the 
Model Standards for Pharmacy Compounding, Canada closely fol-
lowed the U.S. guidelines and policies for compounding drug prod-
ucts.201 This is exemplified by Canada’s “Policy on Manufacturing 
and Compounding Drug Products in Canada” that addresses the no-
tion that pharmaceutical compounding is not a means of bypassing 
federal drug review and approval systems.202 More specifically, 
compounded drug products must result in a customized medication 
that does not duplicate an existing federally approved drug.203 
Health Canada also utilizes the U.S. Pharmacopoeia guidelines for 
the preparation of sterile and non-sterile compounds.204 While fol-
lowing U.S. guidelines has not been detrimental to Canada’s regu-
latory framework thus far, should Health Canada continue to pursue 
the U.S.’ currently enacted Compounding Quality Act, regulatory 
loopholes may arise. 
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V. CURRENT AND FUTURE IMPLICATIONS ON PRICES AND 
AVAILABILITY OF DRUG COMPOUNDS 
A. United States 
While the production of safe compounded drugs remains a top 
priority for the FDA, the Drug Quality and Security Act has made it 
less financially feasible for traditional compounding pharmacies to 
be profitable in the market.205 Operating with lower profits, several 
pharmaceutical compounding companies have been forced to reduce 
the number of drugs produced.206 Leiter’s Compounding Pharmacy, 
at one time producing an astonishing 1,800 drugs, was compelled to 
lower production to only 11 drugs due to new FDA restrictions.207 
In addition, compounding pharmaceutical companies have been ob-
ligated to employ fifteen to twenty quality assurance staff members 
to ensure compliance with the stricter regulations.208 The combina-
tion of reducing the number of drugs produced,209 hiring additional 
employees,210 and producing compounded drugs in small quantities 
due to rigid prescription requirements,211 has driven up the cost of 
production tremendously.212 
Ultimately, consumers are the ones paying the price as many 
compounded drugs will be either unavailable or are priced out of the 
reach of those that need them.213 According to Charles Leiter, owner 
of Leiter’s Compounding Pharmacy, physicians are finding it diffi-
cult to obtain medications necessary to treat their patients.214 In par-
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ticular, Avastin utilized by retina physicians has been nearly impos-
sible to acquire.215 Avastin, an FDA approved medication used as a 
chemotherapeutic treatment for colon cancer, has also been success-
fully used for diseases such as macular degeneration, retinal vascu-
lar disease, and diabetic retinopathy.216 In creating proper doses for 
retinal usage, compounding pharmacies must divide a four milliliter 
marketed dose into sixty single-use doses with each dose costing 
patients sixty dollars.217 However, due to FDA enforcement and the 
prescription requirement under section 503A, many compounding 
pharmacies have stopped offering Avastin making it practically un-
available.218 Without the compounding pharmacies’ offerings of 
Avastin, patients are left with two FDA approved drugs, Lucentis 
and Eylea, costing approximately $2,020 and $1,950 respectively.219 
In such cases, many patients, with or without insurance, simply can-
not afford the exorbitantly expensive medications, while viable 
medications costing 97 percent less than their FDA approved coun-
terparts are simply unavailable due to government overregulation.220 
Simply stated, in the government’s efforts to protect consumers 
through strict regulation and requirements, smaller compounding 
companies are unable to comply due to the high costs of meeting 
those requirements and are penalized to the point that consumers 
lose their access to needed medications.221 
On January 4, 2018, the FDA announced that the USP standards 
are currently under revision with the intent of raising the standards 
for drug compounding production.222 All compounding pharmacies 
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under 503A will be required to implement the USP’s revised stand-
ards.223 Although there is no indication as to the manner in which 
the USP standards will be modified, it is reasonable to assume that 
pharmacists will need to be retrained and be reassessed to prove 
competency. Furthermore, compounding pharmacies may be re-
quired to purchase new or additional equipment to ensure the safe 
preparation of sterile drug compounds. While a safer product is po-
tentially in our future, the additional requirements placed on com-
pounders may cause an economic burden so great as to cause smaller 
compounding pharmacies to close shop. 
Additionally, should Congress amend the Compounding Quality 
Act, mandating outsourcing facilities to register with the FDA, those 
outsourcing facilities may choose to close their doors as well. For 
exemption from the prescription requirement in section 503A, out-
sourcing facilities need to meet the following criteria: 
1. The outsourcing facility is in compliance with CGMPs.224 
2. A compounded drug can not contain bulk drug substances 
unless the substance appears on a list established by the secretary 
when there are clinical needs.225 
3. Ingredients (other than bulk substances) used in compounds 
must comply with standards of the USP, NF, or of another compen-
dium.226 
4. The drug does not appear on a list published by the Secretary 
because it’s unsafe or ineffective.227 
5. The drug is not an “essential copy” of one or more approved 
drugs.228 
6. The drug doesn’t present demonstrable difficulties for com-
pounding.229 
7. The outsourcing facility has a proper control system when 
dealing with compounded drugs or ingredients that are subject to the 
FDA’s risk evaluation and mitigation strategy.230 
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8. The outsourcing facility that compounds the drug is the only 
entity that can sell the drug.231 
9. The drug must be labeled appropriately.232 
The difficulty in meeting these requirements is obvious as the 
FDA has issued warning letters to eight out of the seventy-three reg-
istered outsourcing facilities, stating that they are failing to meet the 
requirements under section 503B.233 The FDA has also ordered two 
facilities to cease sterile operations and recall dispensed sterile prod-
ucts.234 The combination of increased FDA scrutiny along with sig-
nificant increases, approximately five to ten times, in costs to 
achieve the CGMP requirements,235 has outsourcing facilities ques-
tioning whether the financial investment is worth making. As a re-
sult, with massive shortages of over 300 essential drugs, in which 
outsourcing facilities normally assist in meeting those needs,236 con-
ditions will continue to deteriorate and leave patients without medi-
cations to treat their ailments. 
Should the U.S. maintain its narrow and single approach towards 
public health protections, patients will no longer have access to ef-
fective and affordable treatments. As such, federal and state laws 
and regulations need modification to not only ensure the safety of 
compounded drugs, but to ensure drug availability with reasonable 
consumer costs. Creating a system of uniform accountability be-
tween states, along with shifting some responsibility to the com-
pounding companies in a similar fashion to NAPRA Model Stand-
ards, may be an effective way to accomplish this balance. The more 
stringent FDA restriction created through the Compounding Quality 
Act does not seem to achieve this necessary balance. 
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B. Canada 
The NAPRA’s strict standards for facility design and equipment 
for sterile compounding have resulted in costly and time consuming 
renovation for many compounding facilities.237 Regarding facility 
design, some of the requirements include the following: 
1. A reserved area large enough for sterile preparations – en-
sure good flow of people, equipment and materials; and allow dis-
infecting and cleaning without constraint.238 
2. Heating, ventilation, and air conditioning systems must be 
designed to minimize risk of airborne contamination in controlled 
rooms.239 Specifically return air intakes must be placed at the bottom 
of the walls to push any possible contaminants downward.240 
3. Controlled rooms must not have any windows or openings 
that lead to the outside or non-controlled rooms.241 If they do, they 
must be sealed.242 
4. A clean room, where atmospheric properties are con-
trolled.243 
5. An anteroom, which is the transition space between a non-
controlled and controlled room.244 
According to Sabrina McLean, a pharmacist and compounding 
consultant in Dartmouth, Nova Scotia, some pharmacies producing 
sterile compounds “would have to do full renovations to meet the 
requirements.”245 In achieving these lofty goals, some of these phar-
macies have discontinued operations, while others have been forced 
to decrease production significantly.246 Lawtons, a Nova Scotia 
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pharmacy that participates in compounding, has dramatically de-
creased its compounding activity as an alternative to major facility 
renovations based on the new regulations.247 Unfortunately, Cana-
dian consumers, just like their peers in the U.S., may have no choice 
but to incur higher costs for their compounded drugs or simply do 
without as many pharmaceutical compounding companies are being 
overregulated out of the market. 
Canada has not seen the full impact of the new regulations on 
drug prices and availability simply because the NAPRA has recently 
published the Model Standards for Non-Sterile Preparations.248 It is 
McLean’s assertion that the new regulations for non-sterile com-
pounding will require the use of more expensive protective equip-
ment.249 While it is reasonable to speculate that the costs associated 
around non-sterile compounding will only be a small percentage 
compared to what it is for sterile compounding, costs may still be 
high enough to deter pharmacies from producing non-sterile com-
pounds. 
On the other hand, even with the NAPRA Model Standards 
largely increasing the overhead costs, some compounding pharma-
cies are not struggling with offsetting these high costs due to gener-
ous dispensing and compounding fee subsidized payments by pro-
vincial drugs programs.250 In August 2017, Manitoba placed a $30 
cap on compounding fee payments for non-sterile compounded 
drugs and a $60 cap for sterile compounded drugs per prescrip-
tion.251 Because pharmacies individually determine dispensing and 
compounding fees, clients became concerned that they would be re-
quired to pay additional fees above and beyond the payment caps.252 
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This was especially true for compounded drugs that could cost hun-
dreds of dollars to produce.253 Quinton Didyk, an owner of a com-
pounding pharmacy that serves over half of the pharmacies in Man-
itoba, asserts that his customers will not be charged additional com-
pounding fees due to the generous payment caps.254 Additionally, 
the policy contains an exemption clause which states that specialty 
compounds or compounds that take more than forty-five minutes to 
prepare will be subsidized by provincial drug programs.255 These 
regulated compounding fee payments allow compounding pharma-
cies to remain competitive and profitable while keeping prices af-
fordable. 
These fee payments are not quite as generous in other prov-
inces.256 Most provinces have dispensing fee payment caps around 
$8-12.257 For example, Ontario has a cap starting at $8.83 and goes 
up to $13.25 depending on the location.258 With such low payment 
caps, compounding facilities in other provinces are forced to choose 
whether to remain competitive, but less profitable, or gamble by 
charging higher fees which would require consumers to reach in 
their pockets. In the end, the latter choice may likely lead to a less 
profitable outcome as consumers may seek other sources of remedi-
ation. Should provinces decide to increase or match the payment 
caps set in Manitoba, compounding pharmacies would find it more 
financially feasible to remain and comply with the NAPRA Model 
Standards, thereby keeping compounded drugs available and afford-
able to consumers throughout Canada. 
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VI. CONCLUSION 
With an ever-increasing population, drug shortages, and a grow-
ing need for customized medications, drug compounding will con-
tinue to be an essential component in the world of pharmaceuticals. 
While these drugs are desperately needed to fill the void in the mar-
ket, the business of pharmaceutical compounding remains danger-
ous and, for the most part, unregulated in the U.S. despite Congress’ 
passing of the Drug Quality and Safety Act, which defines state and 
federal authority and responsibilities in order to ensure consumer 
safety.259 This has left many gaps in the regulatory framework, al-
lowing sterile compounding pharmacies to function unchecked and 
unaccountable.260 Incommensurable standards of quality and re-
quirements for training between states, in conjunction with misa-
ligned state and federal laws and regulations, continues to be the 
greatest impediment in the delivery of safe and high quality phar-
maceuticals.261 Moreover, Congress tied the FDA’s hands when it 
opted against mandating outsourcing facilities from having to regis-
ter with the FDA.262 The FDA cannot effectively regulate outsourc-
ing facilities when states undermine the incentives the FDA pro-
vides to voluntarily register.263 At the same time, states that enforce 
regulations set by the Drug Quality and Safety Act have made it less 
financially viable for traditional compounding pharmacies due to 
strict scrutiny over sterile compounding practices and procedures.264 
Some pharmacies have chosen to drastically reduce the number of 
compounded drugs produced, while others have simply ceased op-
erations.265 Ultimately, consumers of drug compounds have less 
availability, are faced with higher prices, and remain vulnerable to 
potentially unsafe medications. 
Similarly, Canadian pharmaceutical compounding continues to 
play a crucial role in the healthcare system. While it remains to be 
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seen whether the NAPRA Model Standards will be effective in en-
suring consumer safety, the NAPRA has clearly placed the respon-
sibility into the hands of pharmacy professionals.266 Unlike the 
Compounding Quality Act in the U.S., the Model Standards provide 
compounding pharmacies with detailed guidelines in the preparation 
of compounds.267 These clear and concise guidelines allow provin-
cial/territorial authorities to easily enforce and maintain these high 
standards.268 On the negative side, however, while the enforcement 
of such rigid NAPRA Model Standards maintains high compound-
ing quality standards, costs are driven up by the requirements for 
upgraded facility design, sophisticated equipment, and better trained 
personnel.269 Dramatically higher production costs have already 
driven several Canadian compounding pharmacies out of the mar-
ket.270 However, provinces may be able to find ways to incentivize 
pharmacies, thereby offsetting the costly changes required by the 
Model Standards.271 Raising compounding fee payment caps would 
be an effective method of achieving this goal. With a bit of tweaking 
and creativity, Canada’s regulatory initiatives appear to hold the 
most promise for procuring safe drug compounds without the risk of 
diminished availability or exorbitant prices. 
 The U.S. and Canada face a future which will require addi-
tional governmental action to secure the successful delivery of qual-
ity compounded medications. As noted by Michael Carome, MD, 
director of the Public Citizen Health Research Group in Washing-
ton, DC, “[a]lthough compounded drugs serve an important need for 
patients whose medical needs cannot be met by an FDA-approved 
drug, it is imperative that healthcare providers and patients alike rec-
ognize that compounded drugs pose a higher risk to patients than 
FDA-approved products.”272 Whether additional federal legislation 
is needed to bring compounded drugs up to FDA-approved stand-
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ards is a relevant question. In either case, a close working relation-
ship between federal and state/provincial levels must exist for com-
pounding to successfully and safely coexist with traditional pharma-
ceutical manufacturers. While both countries have made headway 
into developing effective strategies to accomplish these goals, col-
laboration, creativity, and a broad-minded willingness of state or 
provincial/territorial and federal governments to work together for 
the good of public health will be key to making compounding phar-
macies profitable, safe, and able to meet the future demands of an 
ever-growing population. 
